An asthma drug developed by Sanofi and Regeneron reduced asthma attacks by 87% in a mid-stage drug trial. More
-
-
Sponsored By:
-
Sponsored By:
Pharmaceuticals
Recent Articles
1 Stock to Buy, 1 Stock to Short: Small-Cap Pharma
The charts are showing an intermediate-term buy and a short-term shorting opportunity in these small-cap pharmaceutical stocks. More
Should I Buy Pfizer? 3 Pros, 3 Cons
Pfizer's Q4 earnings put a small scare into investors a couple weeks back, but the pharma behemoth is built too well to ignore. More
1 Stock to Buy, 1 Stock to Short: Pharmaceuticals
We've got a micro-cap stock that looks to go even lower and a symmetrical continuation triangle that spells more upside ahead for Arena Pharmaceuticals (ARNA). More
Belviq Is Not the Next Fen-Phen … Probably
Arena Pharmaceuticals' withdrawal of its European application for Belviq has turned the stock into a three-ring circus. Don't panic -- just get the facts straight. More
Baxter’s Alzheimer’s Drug Fails in Study
A drug from Baxter International aimed at reducing mental decline in Alzheimer's patients failed to show improvement compared to a placebo in a clinical trial. More
Pfizer Spares Patients From Erectile Dysfunction Embarrassment
Pfizer has created an industry first by selling its successful Viagra pill directly to consumers -- a move that has implications for major drugmakers and pharmacies alike. More
